Imatinib induces apoptosis in CLL lymphocytes with high expression of Par-4

Leukemia. 2005 Jun;19(6):1103-5; author reply 1105-6; discussion 1106-7. doi: 10.1038/sj.leu.2403739.
No abstract available

Publication types

  • Comment
  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Agents / pharmacology*
  • Apoptosis / drug effects*
  • Apoptosis Regulatory Proteins
  • Benzamides
  • Humans
  • Imatinib Mesylate
  • In Vitro Techniques
  • Intracellular Signaling Peptides and Proteins / genetics*
  • Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy*
  • Leukemia, Lymphocytic, Chronic, B-Cell / physiopathology
  • Lymphocytes / cytology
  • Lymphocytes / drug effects
  • Lymphocytes / physiology
  • Piperazines / pharmacology*
  • Pyrimidines / pharmacology*

Substances

  • Antineoplastic Agents
  • Apoptosis Regulatory Proteins
  • Benzamides
  • Intracellular Signaling Peptides and Proteins
  • Piperazines
  • Pyrimidines
  • prostate apoptosis response-4 protein
  • Imatinib Mesylate